header logo image


Page 677«..1020..676677678679..690700..»

Global Type-1 Diabetes Treatment Market | Industry Size, Growth Opportunities, Competitive Analysis and Forecast to 2024 – Nyse Nasdaq Live

February 18th, 2020 5:51 pm

Research study on Global Type-1 Diabetes Treatment Market Examination of Market Segmentation Including Product Type, Application, And Regions

Global Type-1 Diabetes Treatment Market comprises the estimation of the market including industry analysis, size, share, growth, trends, outlook, and forecasts 2019-2024. Global Type-1 Diabetes Treatment the industry is just the resource that players need to strengthen their overall growth and establish a strong position in their business. The report analyzes historical data, facts, current growth factors, and market threats with a competitive analysis of major market players. The report covers consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges. The report presents the scope of different segments and applications that can potentially influence the global market in the projection period from 2019 to 2024.

Get a Sample Copy at:https://www.mrinsights.biz/report-detail/214865/request-sample

The report represents the aspects and descriptions of the global Type-1 Diabetes Treatment market by maps, bar graphs, pie diagrams, and other visual representations. It gives top to bottom investigation of the potential portions including item type, application, end client and their commitment to the general market size. It further covers the present situation and the development possibilities of the industry for 2019-2024. Research experts have utilized industry-best essential and auxiliary research approaches to organize this meticulous and complete research study on the worldwide market.

The well-established key players in the market are:Astellas Pharma, Abbott Laboratories, Merck, Novo Nordisk, Sanofi, Eli Lilly, Novartis, AstraZeneca, Pfizer Inc., Boehringer Ingelheim GmbH, Mannkind Corporation, Macrogenics, Inc., Braun Melsungen AG

The report explores Type-1 Diabetes Treatment business policies, trading, market channels, market volume, providers of raw material and customer data, demand & supply ratio. Geographic division relies on:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Key Details Outlined In The Report:

The report deals with the key factors driving the commercial landscape of the global Type-1 Diabetes Treatment market over the analysis period. Market share and growth rates accounted for by every application over the estimation timeline are encompassed in the report. It provides analysis on the industry chain scenario, key market players, market volume, upstream raw material details, production cost, and marketing channels. The report covers analysis on consumption volume, region-wise import/export analysis and forecast market from 2019-2024.

ACCESS FULL [emailprotected]https://www.mrinsights.biz/report/global-type-1-diabetes-treatment-market-growth-status-and-214865.html

Destinations of The Research Study:

Moreover, the report gives revenue estimates of the global Type-1 Diabetes Treatment market based on top industry players, their product type, applications, and regions. It has mentioned the production volume and consumption volume during the forecast period. Then, the sale worth is for varied sorts, applications, and regions also are enclosed.In addition, sort wise and application wise consumption figures also are provided.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See the original post here:
Global Type-1 Diabetes Treatment Market | Industry Size, Growth Opportunities, Competitive Analysis and Forecast to 2024 - Nyse Nasdaq Live

Read More...

Northern Ireland ‘Diabetic Duo’ who have gone viral with online videos that smash stigma of life with the illness – Belfast Telegraph

February 18th, 2020 5:51 pm

Two Co Down students have become the stars of a new series of videos - which have gone viral - aimed at making it okay to have diabetes. Best friends Ellen Watson (19) and Beth McDaniel (20), from Banbridge, are smashing the stigma of Type 1 diabetes - a lifelong condition that causes a person's blood sugar level to become too high and for which daily injections of insulin are needed - thanks to their hugely popular TikTok videos.

alling themselves the Diabetic Duo, the young women have amassed hundreds of thousands of followers in just a few months through their refreshing, light-hearted posts about living with Type 1 diabetes.

TikTok is a popular video-sharing social network service used to create short film clips which can last from three to 15 seconds.

After posting their first video last October, Ellen and Beth knew they had hit a nerve when it was viewed overnight by 500,000 people and eventually scored more than 700,000 hits.

They were then inundated with messages from young people around the globe congratulating them on raising awareness about living with diabetes.

Ellen and Beth - who are both studying at Ulster University - live together, work together at the weekends, are cheerleaders and love to shop.

We use our free style libras to check our blood sugar levels using our phones they are a gift from god #fyp #diabeticduo #belfast #trending

Ellen has lived with diabetes since the age of six and was shocked when Beth was diagnosed just last September.

The two friends support each other, counting calories to ensure their diets are healthy and keeping tabs on monitoring blood sugar levels.

Ellen knows what it's like to grow up under the shadow of diabetes, having tried to hide it for years from her school friends, which is why she is thrilled that the videos are having such a big impact.

"I grew up with diabetes and have had it for as long as I can remember," she says. "When I was really young I just did what my mum told me and then as I got older I had to learn to keep an eye on my sugar levels myself.

"I became really conscious of it in high school when I was 13. I didn't want people to know I had it and I would have tried to inject myself under the table in the canteen at lunchtime without anyone knowing.

"When I got a bit older I did grow to accept it a bit more and see the positive side. I have great community support with my doctor and nurses who are all lovely and show you how to live with it.

"My mum Sharon is a nurse and she always kept me right. New technology has really helped make life with diabetes a lot easier."

Ellen was on hand to support her best friend Beth when she was diagnosed in September of last year - incredibly, within just a week of her 12-year-old sister also being diagnosed.

Injecting in strange places#diabeticduo #foryoupage #belfast #holylands #t1dcat #hypo #trending

"We have no family history of diabetes but last August my little sister Grace took sick and was diagnosed with diabetes which was a big shock for our family," Beth says.

"Seven days later, on September 4 - a day I will never forget - I, too, was diagnosed. My parents were still in shock over Grace's diagnosis and just couldn't believe it when I was told I had it, too.

"I knew it was diabetes as I had all the symptoms. I was really sluggish and didn't want to get out of bed and was very thirsty. I also had blurred vision and I felt very irritable.

"I believed in my head that I had it and my dad took to me to hospital where it was diagnosed. My mum was devastated.

"At first I found it really hard to come to terms with and I cried every day for the first two weeks.

"I never liked needles and I would have sat staring at my belly for 10 minutes before plucking up the courage to inject myself.

"The finger-pricking to check blood sugar levels was also really sore.

"Ellen and I share accommodation at university and we just sit at the dinner table some nights and laugh because we always shared everything and we can't believe we now both have diabetes.

"We inject at the same time and we both count our calories to make sure we are eating property.

"Ellen has been such a huge support and I really wouldn't have coped so well over the last few months without her."

A great support to each other, the girls have been inseparable since they first met four years ago while working in the same shoe shop in their home town of Banbridge.

They hit it off immediately and not only did they have a lot of interests in common, but they both looked alike.

"We just clicked and everyone thinks we are twins because we look so much like each other," Beth laughs.

"We even picked similar courses at the same university. Ellen is studying marketing at the Ulster University and I'm studying communications, advertising and marketing.

"We also live together in the same student accommodation and that has brought us even closer together."

Type 1 diabetes is different to Type 2 - the latter is usually associated with lifestyle, in particular being overweight, and presents later in adult life.

Ellen and Beth say that a general lack of understanding in the difference between the two is a huge reason why they believe there is a stigma surrounding living with diabetes.

People with Type 1 diabetes are insulin-dependent as their pancreas produces little or no insulin - the hormone which regulates blood sugar.

People with Type 2 diabetes can manage the disease with a healthy lifestyle and diet. However, most also have to take medication.

The girls have been breaking down barriers by recording videos showing them openly injecting insulin and proudly wearing their sugar monitoring discs on their arms during nights out.

A new device called the FreeStyle Libre is a glucose-monitoring disc which can be worn on the arm and, linked to a phone app, monitors blood sugars automatically. While you may still need to do some finger-prick tests, this nonetheless provides an enormous benefit.

Indeed, Ellen says it has revolutionised how she is able to manage her diabetes and even her mum has access to the same app which displays a graph of her blood sugar levels throughout the day.

Wearing the arm sensor, which is around the size of a two-pence piece, on their videos has endeared them to other young people who felt the need to hide their diabetes.

When you and your bestie have a hypo at the same time #diabeticduo #fyp #belfast #foryoupage #hypo #trending #besties

The students aim to keep their videos funny while promoting the message that it is okay to have diabetes.

They have been astonished by the reaction.

"I was constantly asked if I was overweight as people automatically assume that is why I have diabetes and with the videos we've been able to shatter that myth," Ellen says.

"People are quite shocked that we are young and eat well and look after ourselves and still have diabetes.

"We already did some fun videos as 'the iconic duo' as we are always together and always doing the same thing and even wear the same outfits.

"We thought we should make one for the craic for TikTok and add diabetes as an element - overnight it went viral with half a million views and in the end more than 700,000 people watched it and we just couldn't believe it. People saw the scanner on our arms and were shocked that we would wear it so openly on a night out.

"For us it is a way to create a bit of fun out of a lifelong illness.

"We've had messages from all over the world, from Scotland, Australia and America, and we just seem to be getting more and more every day.

"Many are from children and young people our age who are asking us questions and, while we know we are not in a position to give medical advice, we are happy to support people who contact us.

"I feel that it really would have helped me if I had something similar to look out for when I was younger as there was no one I knew my age who had diabetes and who I could relate to."

Close

Fun times: The Diabetic Duo are often mistaken for twins

Kevin Scott

Beth agrees and adds: "It is all about changing the stigma as a lot of people don't understand the difference between Type 1 and Type 2 diabetes. I love how we are inspiring people and it's great to be able to post positive things online.

"I think it is really important to bring positivity to it with a bit of fun at the heart of it. People can be really negative about it and we are glad to be able to bring it out in the open and show we are not uncomfortable with it.

"We've done a range of funny videos including one where we pretended to be our nurses checking our blood cells and the nurses and doctors in our local practice said they loved it.

"We also did one on injecting insulin in strange places and we videoed ourselves injecting in front of a police car, while doing our cheerleading and eating a sausage roll in Greggs and that was viewed by half a million people.

The response has been incredible and we are constantly having people come up to us in shops and the street recognising us as the Diabetic Duo. We feel like local celebrities!"

You can watch Ellen and Beth on the TikTok app via @diabeticduo. Beth also writes a beauty blog you can find at bethymcdaniel.wordpress.com

The number of people in Northern Ireland living with Type 1 and Type 2 diabetes is now 100,000, according to figures published by http://www.diabetes.org.uk. This number includes the estimated 12,000 who have not yet been diagnosed with Type 2 diabetes.

Prevalence of diabetes in NI is now over 5.7% and approximately 90% of diabetes cases are Type 2, the NI Audit Office reports.

Type 1 diabetes

Type 1 has no relation to diet or lifestyle and it is not clear what causes it.

The cells of the pancreas which make insulin are attacked which means that insulin production is suppressed.

Because insulin regulates blood sugar, without this control in place glucose levels in the blood build up.

Symptoms: before diagnosis, your body tries to remove glucose through the kidneys, which means you go to the toilet a lot.

The patient can be very thirsty, feel tired more than usual, lose weight unexpectedly and have blurred vision. These symptoms can present within days or weeks and the patient should seek medical attention as soon as possible.

Managing Type 1 diabetes: insulin must be injected or delivered to the body via a pump. Blood sugar levels should be checked several times a day.

Type 2 diabetes

Six out of 10 people have no symptoms when they're diagnosed with Type 2 diabetes. However, symptoms are similar to those for Type 1.

Managing Type 2 diabetes: most people need medicine to help keep blood sugar levels as normal as possible. Sticking to a healthy diet and keeping active will help you manage blood sugar.

Around 2.5 hours of activity a week is recommended - this could include fast walking, climbing stairs and doing more strenuous housework or gardening.

Losing weight if you're overweight is important as it will help your body to lower your blood sugar level, and can improve blood pressure and cholesterol.

Regular monitoring and check-ups are important as complications of Type 2 diabetes can include heart disease and stroke, nerve damage, foot problems, vision loss and kidney problems.

Sources: http://www.diabetes.org.uk and http://www.nhs.uk

Read the original post:
Northern Ireland 'Diabetic Duo' who have gone viral with online videos that smash stigma of life with the illness - Belfast Telegraph

Read More...

Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes – GlobeNewswire

February 18th, 2020 5:51 pm

CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- DiasomePharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with type 1 diabetes (T1D).

One of the trials investigators, Bruce Bode, M.D., a diabetes specialist with Atlanta Diabetes Associates and clinical associate professor in the Department of Medicine at Emory University, added, The OPTI-1 study may be the first clinical trial to demonstrate the impact of the combined effects of liver targeted insulin and physiologically driven changes in the ratio of mealtime to long-acting insulin regimens. These results provide additional evidence that targeting insulin to the liver induces a more physiological response. When added to insulin, HDV may allow patients to optimize the amount of short-acting and long-acting insulin they need to reduce the incidence of hypoglycemia while still achieving positive long-term health outcomes.

This open-label, multicenter study was designed to evaluate the effect of HDV added to rapid-acting mealtime insulin on A1C, hypoglycemia, and bolus and basal insulin dosing in adult T1D patients with baseline A1C levels between 6.5% and 8.5%. Patients underwent a three-month run-in period on standard-of-care therapy followed by three months of treatment with HDV added to mealtime insulin in conjunction with optimized basal insulin doses. A total of 61 T1D patients were enrolled at eight United States trial sites. After patients were treated with standard-of-care Lispro or Degludec during the run-in period, they were randomized into one of two groups: HDV-Lispro (HDV-L) in conjunction with a 10% reduction in Degludec or HDV-L in conjunction with a 40% reduction in Degludec.

The completion of this clinical trial marks an important milestone for the continued development of HDV, said Robert Geho, chief executive officer of Diasome. Results from this study, which we plan to present at upcoming conferences, continue to support the hypothesis that improved mealtime insulin delivery to the liver should have an important and positive effect on overall glycemic control. We are excited about these results and look forward to sharing additional details soon.

About Hepatocyte Directed Vesicle (HDV) TechnologyHDVs are the most advanced technology designed to restore normal physiology and potentially offer protection against hypoglycemia for patients with diabetes. Only 20-50 nanometers in size, these two-layered microscopic discs are designed to bring insulin to receptors highly expressed by liver cells. Liquid HDV can be mixed with any commercially available insulin prior to administration and is compatible with any insulin delivery system.

About Type 1 Diabetes (T1D)T1D is a chronic, auto-immune disease characterized by the inability of the pancreas to produce insulin, which leads to elevated blood sugar levels. Diabetes costs represent a large burden to both patients and the healthcare system. More than 1.25 million Americans are living with T1D and there is no cure.

About OPTI-1The 24-week, open-label, multiple dose trial is designed to assess the safety, tolerability and efficacy of hepatocyte directed vesicle (HDV) technology when added to rapid-acting mealtime insulin. All patients received insulin Lispro and Degludec during a 12-week run-in period. After completing the run-in period, patients were randomized to a treatment group of either HDV added to Lispro (HDV-L) while continuing Degludec at a dose reduced by 40% or HDV-L while continuing Degludec at a dose reduced by 10% for 12 weeks of treatment.

About Diasome Pharmaceuticals, Inc.Diasomes hepatocyte directed vesicle (HDV) technology is the only pharmaceutical insulin additive being developed to prevent hypoglycemia by restoring normal liver physiology in patients with diabetes. HDV technology is a Phase 3-ready asset designed to improve the safety and efficacy of all insulins. For more information, visit http://www.diasome.com or follow us on Twitter.

Investor Contact:Jeremy FefferLifeSci Advisors, LLCjeremy@lifesciadvisors.com+1.212-915-2568

Media Contact:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com+1.646.876.5196

See original here:
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes - GlobeNewswire

Read More...

Type 2 diabetes: Best bread to choose if you want to lower blood sugar – Express

February 18th, 2020 5:51 pm

Type 2 diabetes is a condition which results in the body losing control of the amount of glucose in the blood, causing blood glucose levels becoming too high. If blood glucose isnt controlled properly and stays too high, it can lead to a number of problems, including kidney failure, nerve damage, heart disease and stroke.

Eating a regular poor diet can increase a persons risk of developing type 2 diabetes, so making diet changes is recommended.

Carbohydrates you eat and drink are broken down into glucose, and the type and amount you consume can make a difference to a persons blood glucose levels and diabetes management.

So when it comes to one of the famous carbohydrates, bread, what type is considered best or what advice should you follow?

Diabetes UK explains: There are two types of carbohydrate: starchy carbohydrates and sugars.

READ MORE:How to live longer: People with this condition 50 percent more likely to die early

Bread falls into the starchy carbohydrate category. All carbohydrates affect blood glucose levels.

Carbohydrate requirements vary between individuals and depend on age, gender, weight and physical activity.

The Reference Intake (RI) of carbohydrate is 230g for women and 300g for men.

These figures are just a guide and are based on the requirements of an average woman and man. Depending on your nutritional goals, you may require less.

DON'T MISS

Most supermarkets and local markets contain different types of bread, the type diabetes charity offers advice for next time youre choosing a loaf.

Per slice, the following types of bread contain:

These could be served with lean chicken, ham, turkey or beef plus chopped tomatoes, grated carrot and cucumber, or reduce-fat cheddar with grated carrot and sultanas.

Sourdough, rye and soda bread may be served with turkey, chicken or Swiss cheese with shredded lettuce, tomatoes and reduced-fat mayo.

These types of bread contain:

Brioche can be served warm with jam or pure fruit spread. It contains:

Garlic and ciabatta bread contain:

Garlic and ciabatta breada are often available to buy already sliced. so you can control your portion sizes.

Naan and chapatti contain:

Diabetes UK says you should try to avoid adding extra butter, margarine or ghee.

The NHS states theres nothing you cannot eat if you have type 2 diabetes, but certain foods should be limited.

It advises: You should eat a wide range of foods including fruit, vegetables and some starchy foods like pasta, keep sugar, fat and salt to a minimum, and eat breakfast, lunch and dinner every day do not skip meals.

Continued here:
Type 2 diabetes: Best bread to choose if you want to lower blood sugar - Express

Read More...

Analysts Mean recommendation for Tandem Diabetes Care, Inc. (TNDM) was 2.00: Is this the key time? – The InvestChronicle

February 18th, 2020 5:51 pm

Tandem Diabetes Care, Inc. (TNDM) is priced at $86.03 after the most recent trading session. At the very opening of the session, the stock price was $86.34 and reached a high price of $87.19, prior to closing the session it reached the value of $83.02. The stock touched a low price of $84.51.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $83.91 on 02/14/20, with the lowest value was $45.61 for the same time period, recorded on 02/26/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging 2.53% during the 52-week period from high price, and 88.62% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $45.61 and $83.91.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.83 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 44.32%, having the revenues showcasing 37.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.91B, as it employees total of 653 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 64.59, with a change in the price was noted +21.14. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +32.58% for the period of last 100 days, recording 1,484,676 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 96.09%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 94.45%. In the last 20 days, the companys Stochastic %K was 93.36% and its Stochastic %D was recorded 92.18%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 44.32%. Additionally, trading for the stock in the period of the last six months notably improved by 50.64%, alongside a boost of 74.57% for the period of the last 12 months. The shares increased approximately by 10.47% in the 7-day charts and went down by 15.07% in the period of the last 30 days. Common stock shares were driven by 37.34% during last recorded quarter.

See the rest here:
Analysts Mean recommendation for Tandem Diabetes Care, Inc. (TNDM) was 2.00: Is this the key time? - The InvestChronicle

Read More...

Omaha eye surgeon travels the world to offer vision and hope – KETV Omaha

February 18th, 2020 5:50 pm

In a couple weeks, he'll go to South America. A few months ago, he traveled to India and this summer he will return. Omaha eye surgeon, Dr. Donny Suh, (pronounced "saw"), is no stranger to volunteer mission trips, first traveling to offer his expertise and services more than 20 years ago with the vising saving organization, Orbis. "I feel very honored and privileged," said Suh, who took a moment from his work as Chief of Pediatric Opthalmology at Children's Hospital and Medical Center, to talk about his volunteer work. Suh also teaches at the University of Nebraska Medical Center and he see patients at Nebraska Medicine where he tackles the most challenging eye issues. He recently returned from a trip to Bihar State, India, where he helped with hospital based training doing cataract surgeries on children. Suh supervised 18 surgeries with trained Indian doctors, showing them how to use the latest surgical equipment provided by the non-profit, Orbis. "This place was particularly advanced. But they were using equipment that was 20 to 30 years old," he said.Surgeons in that hospital perform about 300 surgeries a day. Orbis has 400 volunteer faculty worldwide from more than 30 countries working to prevent blindness around the globe. In Omaha, Suh said he might see two or three children per week with cataracts. About a billion people worldwide have a vision issue that could be prevented or hasn't been addressed. Suh said pediatric cataracts are very common in India because of malnutrition, poor prenatal care and a lack of immunizations. Cataracts make the lens of the eye more opaque, blocking light and causing blindness. "We were in the poorest part of India where everyone lives day to day," said Suh. He said the team of doctors and nurses worked out of an inspiring eye hospital which served multiple purposes. He said the man who built Akhand Jyoti Hospital/School saw the need to serve some of the poorest people on Earth, but also he built it as an educational opportunity to hire girls to work there, train, study, play soccer, and become optometrists."He saw that a lot of girls were being married as teenagers and wanted more for them," said Suh. He said more than 500 young women are now working as eye doctors. Suh often talks about the role vision plays in all aspects of life, especially for a growing child."Vision is responsible for 75 to 85-percent of development. Sight is not just sight. It gives people hope," said Suh. He said he's seen multiple children over the years who couldn't even take their first steps until they were able to see others walk and model the behavior."They would get up and walk the very next day after surgery," he said.KETV has reported on Suh in the past, featuring his efforts to bring vision screenings, training, and an eye clinic to Guatemala. The South Korea native who grew up in dire poverty with his brother and single mom said it's his mission to give back to others, especially in third-world countries. In his recent book, "Catching a Star: My Story of Hope", Suh talks about his childhood, his desire to help others, and life-changing encounters with patients.He writes about a mother who gave birth to a child with multiple genetic and health challenges including a lack of clear vision because of cataracts. Doctors said the baby had just months to live. Suh said the mother begged him to do eye surgery on the child so that when her baby met her in heaven one day, the child would recognize her face. Suh said he was deeply moved by the mother's request and told her, "I will give you my 100-percent so that the baby can see you after surgery."He said, the next day, the baby couldn't stop staring at the mother's face. The child is now 3 and a half years old. "It's truly incredible," said Suh. He believes vision played a large part in helping the child to live. All proceeds from the sale of Suh's book will go toward medical missions and helping children to see. His book is available on Amazon.

In a couple weeks, he'll go to South America. A few months ago, he traveled to India and this summer he will return. Omaha eye surgeon, Dr. Donny Suh, (pronounced "saw"), is no stranger to volunteer mission trips, first traveling to offer his expertise and services more than 20 years ago with the vising saving organization, Orbis.

"I feel very honored and privileged," said Suh, who took a moment from his work as Chief of Pediatric Opthalmology at Children's Hospital and Medical Center, to talk about his volunteer work. Suh also teaches at the University of Nebraska Medical Center and he see patients at Nebraska Medicine where he tackles the most challenging eye issues.

Dr. Suh takes pride in helping to train eye surgeons with the latest technology.

He recently returned from a trip to Bihar State, India, where he helped with hospital based training doing cataract surgeries on children. Suh supervised 18 surgeries with trained Indian doctors, showing them how to use the latest surgical equipment provided by the non-profit, Orbis.

"This place was particularly advanced. But they were using equipment that was 20 to 30 years old," he said.

Surgeons in that hospital perform about 300 surgeries a day.

Orbis has 400 volunteer faculty worldwide from more than 30 countries working to prevent blindness around the globe.

In Omaha, Suh said he might see two or three children per week with cataracts.

About a billion people worldwide have a vision issue that could be prevented or hasn't been addressed.

Dr. Donny Suh has volunteered on mission trips for 20 years.

Suh said pediatric cataracts are very common in India because of malnutrition, poor prenatal care and a lack of immunizations. Cataracts make the lens of the eye more opaque, blocking light and causing blindness.

"We were in the poorest part of India where everyone lives day to day," said Suh. He said the team of doctors and nurses worked out of an inspiring eye hospital which served multiple purposes. He said the man who built Akhand Jyoti Hospital/School saw the need to serve some of the poorest people on Earth, but also he built it as an educational opportunity to hire girls to work there, train, study, play soccer, and become optometrists.

"He saw that a lot of girls were being married as teenagers and wanted more for them," said Suh. He said more than 500 young women are now working as eye doctors.

Suh often talks about the role vision plays in all aspects of life, especially for a growing child.

"Vision is responsible for 75 to 85-percent of development. Sight is not just sight. It gives people hope," said Suh.

He said he's seen multiple children over the years who couldn't even take their first steps until they were able to see others walk and model the behavior.

"They would get up and walk the very next day after surgery," he said.

KETV has reported on Suh in the past, featuring his efforts to bring vision screenings, training, and an eye clinic to Guatemala.

The South Korea native who grew up in dire poverty with his brother and single mom said it's his mission to give back to others, especially in third-world countries.

Suh and his brother were born in South Korea.

In his recent book, "Catching a Star: My Story of Hope", Suh talks about his childhood, his desire to help others, and life-changing encounters with patients.

He writes about a mother who gave birth to a child with multiple genetic and health challenges including a lack of clear vision because of cataracts. Doctors said the baby had just months to live. Suh said the mother begged him to do eye surgery on the child so that when her baby met her in heaven one day, the child would recognize her face.

Suh said he was deeply moved by the mother's request and told her, "I will give you my 100-percent so that the baby can see you after surgery."

He said, the next day, the baby couldn't stop staring at the mother's face. The child is now 3 and a half years old. "It's truly incredible," said Suh.

He believes vision played a large part in helping the child to live.

All proceeds from the sale of Suh's book will go toward medical missions and helping children to see.

His book is available on Amazon.

Originally posted here:
Omaha eye surgeon travels the world to offer vision and hope - KETV Omaha

Read More...

Santen forges ophthalmology partnerships with Verily and WHO – Med-Tech Innovation

February 18th, 2020 5:50 pm

Santen has forged two separate partnerships with Googles life sciences sister company Verilyand the International Telecommunication Union (ITU) whose initiative is supported by the World Health Organisation (WHO).

Both partnerships are aimed to drive the expansion of the latest technological innovations and digital solutions in ophthalmology across Europe and globally.

Combining Santens technology in the ophthalmology field and Verilys expertise in Artificial Intelligence (AI) and building hardware and software-based devices, the new company plans to develop and commercialise ophthalmic devices, including IoT medical devices.

Shigeo Taniuchi, president and COO of Santen said: Santen has actively promoted collaboration and open innovation with various external organisations in order to enhance the Quality of Life for people around the world through eye health. Digital technology is a transformational driver in health and we hope that this joint venture will be a significant step forward in transforming the way of eye care for people around the world.

Dimitri Azar, clinical lead, Opthalmology Programmes at Verily added: We are thrilled to partner with Santen, a global company with an established presence in the ophthalmology industry, to develop novel solutions leveraging AI and microelectronics for better eye care. By combining Santens eye care expertise and Verilys advanced technology, our joint venture is well-positioned to tackle innovative projects in ophthalmology diseases such as glaucoma, dry eye and other opthalmological diseases. Well explore ways to use technology not only to diagnose disease, but to improve disease management, and ultimately, further precision medicine in ophthalmology.

ITU will support Be He@lthy, Be Mobile (BHBM) and will focus preventable non-communicable diseases in the ophthalmology area with the aim of achieving eye health. BHBM is a digital health initiative between the WHO and the ITU in support of the WHO's expansion of services in non-communicable diseases.

This initiative is designed to raise awareness of the prevention and management of non-communicable diseases through the use of mobile phones and digital devices in order to realise healthy lifestyles. It is estimated that almost the entire world population (97%) lives within reach of a mobile cellular signal, and today its service is expanding digital health services and geographic reach, including the distribution of health information and content to end users through SMS (short message service) and digital device apps.

Doreen Bogdan-Martin, director of the ITU Telecommunication Development Bureau, said: "The participation of Santen in BHBM initiative highlights the importance of investing in technologies which can empower people to manage their own health and for medical professionals to better provide care from prevention to diagnosis and treatment. At ITU, we are expanding our partnership and collaboration with various stakeholders in order to bring the benefits of technology to the people, in every area and every walk of life."

The rest is here:
Santen forges ophthalmology partnerships with Verily and WHO - Med-Tech Innovation

Read More...

Connective Tissue Growth Factor Market Size, Share, Top Region, Key Players, Application,Status and Forecast 2027 – Redhill Local Councillors

February 18th, 2020 5:50 pm

The market report envelopes an all-in information of the global Connective Tissue Growth Factor market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Connective Tissue Growth Factor market with DROT and Porters Five Forces analysis. With SWOT analysis, the report offers detailed insights about different players operating within the Connective Tissue Growth Factor market. In addition, the analysts of the report have served the qualitative and quantitative scrutinizing of different micro- and macro-economic factors influencing the global Connective Tissue Growth Factor market.

The Connective Tissue Growth Factor market report examines the consumption patter of each segment and the factors affecting the pattern. In addition, the report focuses on the production footprint of each segment in various industries and regions across the globe.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2550879&source=atm

The Connective Tissue Growth Factor market report helps the readers grasp the changing trend in the industry supply chain, manufacturing techniques and expenses, and current scenario of the end uses in the global Connective Tissue Growth Factor market.

All the players running in the global Connective Tissue Growth Factor market are elaborated thoroughly in the Connective Tissue Growth Factor market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Connective Tissue Growth Factor market players.

The following manufacturers are covered:BLR Bio LLCFibroGen IncProMetic Life Sciences IncRXi Pharmaceuticals Corp

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBLR-200IB-DMDOLX-201PBI-4050Others

Segment by ApplicationHypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

Reports at discounted rates exclusively for new entrants!!! Offer end by midnight!!!

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2550879&source=atm

The Connective Tissue Growth Factor market report answers the following queries:

What the report encloses for the readers:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2550879&licType=S&source=atm

Why choose Connective Tissue Growth Factor Market Report?

See the article here:
Connective Tissue Growth Factor Market Size, Share, Top Region, Key Players, Application,Status and Forecast 2027 - Redhill Local Councillors

Read More...

Lineage Cell Therapeutics to Present New Data From OpRegen and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology…

February 18th, 2020 5:49 pm

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD), have been accepted for presentation at the 2020 Association for Research in Vision and Ophthalmology (ARVO) Meeting, which will be held May 3rd through May 7th, 2020 at the Baltimore Convention Center in Baltimore, MD. The abstract presentation, entitled, "Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results", will be presented as part of the Gene Therapy and Stem cells Session on May 3rd, 2020 from 3:00PM to 4:45PM EDT by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine; Clinical Governance Board, Cincinnati Eye Institute (presentation number 865). The presentation will provide updated data from patient cohorts 1 through 4 of the clinical study and will include data on the first patients dosed with both a new subretinal delivery system as well as with a new Thaw-and-Inject (TAI) formulation of OpRegen.

"We continue to be encouraged by positive data with OpRegen for the treatment of dry AMD," stated Brian M. Culley, CEO of Lineage. "The five patients treated as part of cohort 4, which more closely match our intended patient population, have all demonstrated an increase in the number of letters they can read on an Early Treatment Diabetic Retinopathy Scale (ETDRS), having gained between 10 25 letters. Importantly, the first patient treated using both a new subretinal delivery system and our TAI formulation of OpRegen demonstrated notable improvements in vision, having gained 25 readable letters (or 5 lines) 6 months following administration of OpRegen RPE cells, as assessed by the ETDRS. This represents an improvement in visual acuity from a baseline of 20/250 to 20/100 in the treated eye. These visual acuity measurements are meaningful and can translate into quality of life enhancements to things like reading, driving, or avoiding accidents. With the opening of two leading ophthalmology research centers as clinical sites for our study, we are focused on rapid enrollment so that our clinical update at ARVO can be as mature and informative as possible. Our objective is to combine the best cells, the best production process and the best delivery system, which we believe will position us as the front-runner in the race to address the unmet opportunity in the potential billion-dollar dry AMD market."

In addition, Lineage will present new preclinical results from its Vision Restoration Program, a proprietary program based on the ability to generate 3-dimensional human retinal tissue derived from pluripotent cells. Lineages 3-dimensional retinal tissue technology may address the unmet need of implementing a retinal tissue restoration strategy to address a wide range of severe retinal degenerative conditions including retinitis pigmentosa and advanced forms of AMD. In 2017 and 2019, the Small Business Innovation Research program of the National Institutes of Health awarded Lineage grants of close to $2.3 million to further develop this innovative, next generation vision restoration program.

- The poster presentation, entitled, "Transplantation of organoid-derived human retinal tissue in to the subretinal space of CrxRdy/+ cats)," will be presented as part of the Animal models for visual disease and restoration Session on May 4th, 2020 4:00PM to 5:45PM EDT in Session Number 291 by Igor Nasonkin, Ph.D., Principal Investigator, Director of Research & Development at Lineage (Poster board Number: 2253 - B0162).

- The poster presentation, entitled, " Intraocular biocompatibility of Hystem hydrogel for delivery of pharmaceutical agents and cells," will be presented as part of the Stem cells and organoids: Technical advances Session on May 5th, 2020 between 8:45AM to 10:30AM EDT in Session Number 332 by our collaborator Randolph D. Glickman, Ph.D., Professor of Ophthalmology, UT Health San Antonio (Poster board Number: # A0247).

Story continues

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential applications in Lineages Vision Restoration Program. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005395/en/

Contacts

Lineage Cell Therapeutics, Inc. IR Ioana C. Hone(ir@lineagecell.com) (510) 871-4188

Solebury Trout IR Gitanjali Jain Ogawa(Gogawa@troutgroup.com)(646) 378-2949

View original post here:
Lineage Cell Therapeutics to Present New Data From OpRegen and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology...

Read More...

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg – Times of San Diego

February 18th, 2020 5:49 pm

Share This Article:Mike Bloomberg has a new fan in retired San Diego business journalist and columnist Don Bauder (inset). Photos by Chris Stone, Ellen BauderAt 83, San Diego journalism legend Don Bauder is guarding his health playing hermit at home (to avoid the flu) and venturing out only for doctor visits.

Support Times of San Diego's growthwith a small monthly contribution

Bauder, a Colorado resident since 2003, was forced by heart issues to retire in 2018 as a San Diego Reader columnist. But now he admits hell be questioned about his mental health.

Hes backing Mike Bloomberg for president.

Here I am finally making headway against the heart problems and now I am considered a candidate for the loony bin, Bauder said by email Wednesday.

If exercise and multiple trips to doctors and hospitals will repair my brain as they seem to have helped my heart, I feel I can thwart oncoming dementia, although I have never claimed that I am either stable or a genius as President Donald Trump has. I am at least stable enough to hope that my candidate will not choke on verbal borscht, as Trump does almost every day.

Bauder isnt wearing beet-colored glasses, though.

He concedes that the former New York City mayor once stated that if women wanted to be known for their intelligence, they would spend less time at Bloomingdales and more time at the library.

Bloomberg called the remark a Borscht Belt joke, Bauder said.

The former San Diego Union-Tribune financial editor also noted that Bloomberg once stated that 95% of murderers are male minorities, 15 to 25 who deserve to be pushed up against the wall.

Bauder adds: Democrats desperately need the votes of women, African-Americans and Latinos. New Yorkers have told me that those minorities will never forget, although Bloomberg has renounced his widely criticized stop-and-frisk policy that clearly discriminated against minorities while he was mayor of New York.

But it wasnt until former U-T colleague Logan Jenkins outed himself as a Bloomberg fan that Bauder also emerged from the closet at least locally.

Bauder wrote Times of San Diego:

As a former newspaper columnist and magazine writer, I agree wholeheartedly with Logan Jenkins. After a lot of pondering, I have concluded that Bloomberg is the ideal Democratic candidate. I started out backing Biden, but have become quite disenchanted. Unlike Trump, Bloomberg is a self-made billionaire.

Unlike Trump, who is clearly a sociopath on steroids, as well as a pathological liar and malignant psychotic narcissist, Bloomberg is eminently stable and also brilliant, as he proved in his business career and as mayor of New York City. I would add one thing to what Logan says: we desperately need a female on the ticket. As shown in 2018, females can see through Trump.

I would suggest Kamala Harris; her minority status would help balance the ticket. I worry that Bloombergs stop and frisk mistake will continue to turn off minorities.

Like Bloomberg, Bauder is a former Republican. (From 1960 to 1964, when he was in advertising and PR, Bauder voted for Richard Nixon.)

Since 2004, he says, hes voted for Democratic presidential candidates.

This year, however, I had problems, he wrote Wednesday. I feared that both Bernie Sanders and Elizabeth Warren had gone too far. I dont like Medicare for All. Those who want to keep their private plans should be able to do so. I cant see free higher education for all. Frankly, I think too many students are in college now.

Bauder calls student debt a cancerous problem, but cant see canceling it out.

Should we reimburse those who have already paid off their debt? I cant see giving stipends to families descended from slaves, he said. If anybody deserves to be paid off, its Native Americans, from whom we stole our country.

He said his cautious views left him with moderate choices.

I originally favored Joe Biden, but became disenchanted quickly. I liked Amy Klobuchar from the beginning, and I am happy to see her rising fast, he said. Pete Buttigieg is quite intelligent but needs seasoning. Ditto Tom Steyer.

Bauder considers the 2020 election critical.

Four more years of Trump would be disastrous, he said. Yes, I am concerned about more Russian hacking. Given the close 2016 races in Wisconsin, Michigan and Pennsylvania, we should all worry about Russian hacking this year.

Climate change is the most critical issue for Bauder because if the world doesnt do more to curb greenhouse gases, the world as we know it may suffocate by the end of the century.

This interview was conducted via email.

Times of San Diego: What does Mike Bloomberg offer?

Don Bauder: First: money. Lots of it. Hes worth close to $60 billion, making him 14th-richest in the world, according to Forbes. Unlike Trump, Bloomberg made the money himself. And he is ACTUALLY worth that.

Trump may not even be a billionaire, despite his claims to be worth $10 billion. The biggest advantage of Bloombergs wealth is that he can flood the nation with ads showing that Trump is a phony. Indeed, Bloomberg is already doing that, but you aint seen nuthin yet.

The Democratic Party is hurting for money. Bloomberg is NEEDED. He has not alienated the business community. Right now, money is flowing to Republican coffers because big business particularly pharmaceuticals, insurance, oil and the like is terrified of Sanders and Warren. That river of cash will slow down if the leftists are out of the picture.

As he has proved as New York mayor, Bloomberg is socially liberal and progressive. He supports abortion rights, government-funded stem cell research, same-sex marriage, gun control, environmentalism and routes to citizenship for illegal immigrants.

He is strong on public welfare and is a national leader in the battle against climate change. He wants to enhance the earned income tax credit. But unlike the other candidates, he has support from many in the business community. He is in favor of free trade. He is a fiscal conservative. He balanced New York Citys budget. Facing a crisis, he talked a Republican state Senate into passing a tax increase rather than slashing jobs.

He opposes wealth inequality proposing, for example, that his own taxes should go up. He says generally that taxes for the rich should rise. He would raise corporate taxes from 21% to 28% percent not enough in my judgment, but a good start.

He dislikes the fact that taxes on stock and bond gains are lower than income taxes. He would enhance worker rights and benefits although he has never been considered pro-union. He wants a $15 an hour minimum wage. He favors government-financed welfare projects. He believes rural communities should be more closely connected with urban centers.

During his political career, he has been a Republican, an independent and a Democrat. He knows his way around politics, having been mayor of New York City from 2002 to 2013.

He cracked one time that a short Jew would never be elected president, but I question that. He will absolutely eat up Trump in a debate. It will be obvious that he is 10 times smarter than Trump.

(Bauder cites the same metric in the San Diego mayors race, saying he favors Barbara Bry because of her intelligence.)

Your journalism career is marked by major investigations into scam artists and political boondoggles. What gives you confidence that Bloomberg has genuine concern for the common good and not himself and his affluent cohort?

He favors corporate welfare corporate projects partly funded by government. I consider most such projects to be scams, although few others do. As mayor of New York, he has warned the citizenry of scam artists on the loose. But early in his mayoral term he vetoed a bill against predatory lending.

Why should Sen. Kamala Harris be Bloombergs running mate?

First, the Democrats must have a female on the ticket on the top of the ticket or the vice president. If Bloomberg is at the top, a female must run for the second slot. A minority female would be greatly preferred. Kamala Harris fills that bill. Stacey Abrams or Oprah Winfrey (who says she doesnt want it) would also be excellent.

If Bloomberg doesnt break out in Super Tuesday voting, will he have a shot at winning enough delegates to prevail at Milwaukee Democratic National Convention?

If Bloomberg does poorly, he will have to consider dropping out. If he does drop out, he should continue giving his planned donations to the Democratic Party. Ditto Tom Steyer. Both must continue to give if they are no longer candidates. The Democratic Party is not in good financial shape. If Bloomberg loses, I would hope Sherrod Brown, senator of Ohio, would get in the race.

Bloomberg has credibility from his mayor terms and gun-control and climate-change work. But he was elected in a very liberal environment. Could he challenge Trump in red states?

You make a good point that Bloomberg might not go over well in red states where uneducated voters are abundant. Many Americans hate New Yorkers unfortunately, often for good reasons. But although Bloomberg is short in stature, many voters will realize that he would be the real alpha male in the race. He is tough and knowledgeable. He would take hard stands on many issues.

Handicap a Trump vs. Sanders contest.

Trump has already called Sanders a communist not a socialist, which he is. So we would have a rerun of Joe McCarthy. If Trump continues to call Sanders a communist, Democrats should call Trump and his ilk fascists. Down and dirty. I think Sanders would take the West Coast and most of the East Coast, including Florida.

But Trump would take states where education levels are low the South, and Northern states such as Montana, Wyoming, Idaho, North and South Dakota, Kansas, Nebraska and other traditionally red (redneck?) states. Colorado, New Mexico and even possibly Arizona could go for Sanders.

Ohio, Indiana and Iowa could go red and Wisconsin and Minnesota might go blue. Illinois could stay blue. Much depends on whether Americans realize that Trump is a pathological liar, sociopath, malignant psychotic narcissist. He seems totally out of control now.

Critics like Paul Heideman call Bloomberg a classic oligarch using his wealth to tilt the economic and political playing field in his favor. Can voters trust someone who uses vast wealth to gain support? How is billionaire Bloomberg better suited to the Oval Office than billionaire Steyer (or anyone else)?

Paul Heideman has a point. You are correct that some voters will see how many ads he spreads around and hold his wealth against him. But these people could be swayed by the wave of advertising.

What Bloomberg can do is massively sponsor ads that emphasize that Trump is a liar showing him saying one thing one day and the opposite the next day. Also, such ads could show that Trumps claims about the economy on his watch are false.

For example, Trump keeps repeating that the economy has done better under him than at other times. This is laughably false. GDP is growing a little over 2% now and there have been many times when it grew 3% and even 4%. Trump says unemployment is the lowest ever, and that is also false. These ads can also show Trump at his most vulgar. That might even go over well in redneck territory, however. Trumps racism through his dog whistles could be emphasized in certain markets but not in redneck areas.

Would Bloomberg address wealth inequality?

Bloomberg is strongly opposed to wealth inequality and says his own taxes should go up. However, he would only raise the corporate tax rate to 28% from 21%. Thats not enough, in my judgment. He believes income taxes for the rich should be boosted. He is also disgusted that taxes on stock and bond profits are lower than taxes on incomes.

He complains that economic growth is concentrated in a small number of regions. He would enhance worker rights and benefits although he has never been known as pro-union a possible negative. He wants a $15 minimum wage. He favors government-financed welfare projects. He would like to see rural communities better connected to urban growth centers. He wants to see research and development in regions needing development.

How is your health?

I saw my cardiologist just two weeks ago. I asked him if I was a candidate for a stent in my two arteries that are only moderately good. He said no. (Background: I have had two quadruple-bypass surgeries. The last one was in 1990. On average, the grafts last 30 years.) But cardiologists (I have had several) say this does not mean I have only two years to go.

The heart itself seems to be OK, but the concern is arteries or grafts from previous surgeries filling up. I will be 84 in May. I dont expect to make it to 90, but with lots of luck I may get half or a third of the way there.

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg was last modified: February 15th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read the rest here:
San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg - Times of San Diego

Read More...

[2020 GUIDE] Global 3D Cell Culture Market : Emerging Innovations Radically Changing The World Industry – Sound On Sound Fest

February 18th, 2020 5:49 pm

Global 3D Cell Culture Market 2020 information: by type (Scaffold-based, Scaffold-free), by end-use/application (Cancer Research, Stem Cell Research, Drug Discovery, Regererative Medicine) by Region (Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa); Forecast till 2028, Market.biz also offering latest industry research value according to the requirement.This report provides you themost up-to-date 3D Cell Culture data in the industry reports, we help you gain a much clearer perspective on the actual 3D Cell Culture market situation, trends, andfuture outlook for different segments.

Tailor-MadeGlobal 3D Cell Culture Market Research Report.

Well-Structured, Analyzed and Explained By Market.biz.

Our report will help you find what you looking for. Get FREE sample PDF:https://market.biz/report/global-3d-cell-culture-market-icrw/134185/#requestforsample

Below is a full list of the ELEMENTs in the Global 3D Cell Culture Industry, which can help organizations to survive and develop their self.

A Regional market Analysis is a quantitative and qualitative assessment of a 3D Cell Culture market. It looks into the size of the 3D Cell Culture business by 2020 both in volume and in value, the various customer segments and 3D Cell Culture buying patterns, the competition, and the economic environment in terms of barriers to entry and regulation.Knowledge is power. It helps businesses strengthen their position. Use market research to gain a better perspective and understanding of 3D Cell Culture market and target audience and ensure you stay ahead of the competition. These regions include-North America, Asia-Pacific, Europe, Africa, South America and the Rest of the world.Also, countries included areU.S., Canada, Mexico, U.K., France, Germany, Italy, China, India, Russia, The Middle East, South-East Asiaand so on.

The 3D Cell Culture Market size is a key component of strategic marketing planning. Knowledge of the size of the target 3D Cell Culture industryallows you to fully assess opportunities and accurately plan your approach and your investments wisely. It provides insights that can drive the future success of the 3D Cell Culture business, including 3D Cell Culture market size, or a total number of buyers for the product or service from different regions. An accurate understanding of market size will provide you with a number of significant advantages that will help you keep your business grow over time. The estimated 3D Cell Culture business value is USDXXbillion in 2028.

Any investment that offers you the benefit of compounding can help you double your investment and build wealth. So, we have calculated 3D Cell Culture Market Compound annual growth rate (CAGR) that shows how much a ones investment grew over a specific period. This report discusses how different 3D Cell Culture industry investments have performed over time. The 3D Cell Culture Industry is growing at a good CAGR of XX%. 3D Cell Culture Market is expected to grow to nearly $XX billion in the coming years.

Herein, we identified direct or indirect market competitors and at the same time,we comprehendedtheir mission, vision, core values, 3D Cell Culture niche market, strengths, and weaknesses. We have provided Porters five forces. It includes three forces from horizontal competition- 1. the threat of substitute products or services, 2. the threat of established3D Cell Culturerivals, 3. the threat of new entrants- and two others from vertical competition1. the bargaining power of3D Cell Culturesuppliers.2. the bargaining power of3D Cell Culturecustomers.Market.bizrecognizes the following companies as the key players in the global 3D Cell Culturemarket that includes-

Insphero, N3d Bioscience, Merck Kgaa, Thermo Fisher Scientific, 3D Biotek, Lonza Group, Kuraray Co, Reprocell orporated and Corning.

It refers to the behavior of the3D Cell Culture consumers in the marketplace and the underlying motives for thosebehavioral trends. Also, here, psychological, personal, and social consumer behavior is studied through focus groups, surveys, and tracking sales history. Our consumer behavior study helps businesses to understand what their consumers value. As a result, 3D Cell Culture businesses can craft their messaging based on what is most important to the subset of the market they are targeting. Not all consumers value the same benefits, so its important for businesses to segment their consumer base.

Finally,with the help of complete research of 3D Cell Culture Market 2020 provides knowledgeable data to the clients using figures, graphs, and flowcharts in the report, the experts represented the analyzed data in a better understandable way. It can assist an individual in making business decisions that can cause achieving swift business growth in 3D Cell Culture business across the world. Also, it discusses business challenges like- Which factors are contributing to the negative or positive growth of the market?

Want to customize this report? Enquire Herehttps://market.biz/report/global-3d-cell-culture-market-icrw/134185/#inquiry

Feel free to share your specific requirements if any, so that we can offer a tailor-made3D Cell Culturereport to suits your requirements.

Contact Us:

Market.Biz (Powered by Prudour Pvt. Ltd.)

Email ID:inquiry@market.biz

Telephone: +1(857)5982522

Link:
[2020 GUIDE] Global 3D Cell Culture Market : Emerging Innovations Radically Changing The World Industry - Sound On Sound Fest

Read More...

Autologous Stem Cell And Non-Stem Cell Based Therapies Market 2020-2025 Booming || Leadinf Players Fibrocell, Genesis Biopharma, Georgia Health…

February 17th, 2020 9:55 pm

TheGlobalAutologous Stem Cell and Non-Stem Cell Based Therapies Marketis expected to reach USD113.04 billion by 2025, from USD 87.59 billion in 2017 growing at a CAGR of 3.7% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015 & 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

For In depth Information Get Sample Copy of this Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Some of the major players operating in the global autologous stem cell and non-stem cell based therapies market areAntria (Cro), Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regenexx, Regeneus, Tengion, Tigenix, Virxsys and many more.

The data and information included in this Global Autologous Stem Cell And Non-Stem Cell Based Therapies business report helps businesses take sound decisions and plan about the advertising and sales promotion strategy more successfully. This Autologous Stem Cell And Non-Stem Cell Based Therapies market research report is generated by taking into account a range of objectives of market research that are vital for the clients success. This report also includes strategic profiling of key players in the market, systematic analysis of their core competencies, and draws a competitive landscape for the Healthcare industry. The Global Autologous Stem Cell And Non-Stem Cell Based Therapies business report includes market shares for global, Europe, North America, Asia Pacific and South America.

Market Definition:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

In autologous stem-cell transplantation persons own undifferentiated cells or stem cells are collected and transplanted back to the person after intensive therapy. These therapies are performed by means of hematopoietic stem cells, in some of the cases cardiac cells are used to fix the damages caused due to heart attacks. The autologous stem cell and non-stem cell based therapies are used in the treatment of various diseases such as neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, infectious disease.

According to World Health Organization (WHO), cardiovascular disease (CVD) causes more than half of all deaths across the European Region. The disease leads to death or frequently it is caused by AIDS, tuberculosis and malaria combined in Europe. With the prevalence of cancer and diabetes in all age groups globally the need of steam cell based therapies is increasing, according to article published by the US National Library of Medicine National Institutes of Health, it was reported that around 382 million people had diabetes in 2013 and the number is growing at alarming rate which has increased the need to improve treatment and therapies regarding the diseases.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

Market Segmentation:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Competitive Analysis:Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The global autologous stem cell and non-stem cell based therapies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for global, Europe, North America, Asia Pacific and South America.

Major Autologous Stem Cell and Non-Stem Cell Based Therapies Market Drivers and Restraints:

Introduction of novel autologous stem cell based therapies in regenerative medicine

Reduction in transplant associated risks

Prevalence of cancer and diabetes in all age groups

High cost of autologous cellular therapies

Lack of skilled professionals

Customization of the Report:

Key benefits of buying the Autologous Stem Cell And Non-Stem Cell Based Therapies Market Report:

This Autologous Stem Cell And Non-Stem Cell Based Therapies Market report will enable both of the sides in market be an established firm or a relative new entrant. It helps the established firms to know about the moves which are being performed by their competitors and also helps the new entrants by educating them about the market situations and the industry trends. This Autologous Stem Cell And Non-Stem Cell Based Therapies Market report is quite fruitful in helping to understand the market definition and all the aspects of the market including the CAGR value and key profiles.

Speak to Author of the report @https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-autologous-stem-cell-and-non-stem-cell-based-therapies-market&raksh

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Go here to see the original:
Autologous Stem Cell And Non-Stem Cell Based Therapies Market 2020-2025 Booming || Leadinf Players Fibrocell, Genesis Biopharma, Georgia Health...

Read More...

Stem Cell Assay Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 – Instant Tech News

February 17th, 2020 9:55 pm

Stem Cell Assay Market Overview:

Global Stem Cell Assay market was valued at USD 536.53million in 2016 and is projected to reach USD 2858.95millionby 2025, growing at a CAGR of 20.43% from 2017 to 2025.

In the report, we thoroughly examine and analyze the Global market for Stem Cell Assay so that market participants can improve their business strategy and ensure long-term success. The reports authors used easy-to-understand language and complex statistical images, but provided detailed information and data on the global Stem Cell Assay market. This report provides players with useful information and suggests result-based ideas to give them a competitive advantage in the global Stem Cell Assay market. Show how other players compete in the global Stem Cell Assay market and explain the strategies you use to differentiate yourself from other participants.

The researchers provided quantitative and qualitative analyzes with evaluations of the absolute dollar opportunity in the report. The report also includes an analysis of Porters Five Forces and PESTLE for more detailed comparisons and other important studies. Each section of the report offers players something to improve their gross margins, sales and marketing strategies, and profit margins. As a tool for insightful market analysis, this report enables players to identify the changes they need to do business and improve their operations. You can also identify key electrical bags and compete with other players in the global Stem Cell Assay market.

Request a Report Brochure @ https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=ITN&utm_medium=003

Top 10 Companies in the Stem Cell Assay Market Research Report:

GE Healthcare, Promega Corporation, Thermo Fisher Scientific Pvt. Merck Millipore, Cell Bio Labs, Hemogenix, Stem Cell Technologies, Bio Rad, R&D Systems, Cellular Dynamics International.

Stem Cell Assay Market Competition:

Each company evaluated in the report is examined for various factors such as the product and application portfolio, market share, growth potential, future plans and recent developments. Readers gain a comprehensive understanding and knowledge of the competitive environment. Most importantly, this report describes the strategies that key players in the global Stem Cell Assay market use to maintain their advantage. It shows how market competition will change in the coming years and how players are preparing to anticipate the competition.

Stem Cell Assay Market Segmentation:

The analysts who wrote the report ranked the global Stem Cell Assay market by product, application, and region. All sectors were examined in detail, focusing on CAGR, market size, growth potential, market share and other important factors. The segment studies included in the report will help players focus on the lucrative areas of the global Stem Cell Assay market. Regional analysis will help players strengthen their base in the major regional markets. This shows the opportunities for unexplored growth in local markets and how capital can be used in the forecast period.

Regions Covered by the global market for Smart Camera:

Middle East and Africa (GCC countries and Egypt)North America (USA, Mexico and Canada)South America (Brazil, etc.)Europe (Turkey, Germany, Russia, Great Britain, Italy, France etc.)Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=ITN&utm_medium=003

Table of Content

1 Introduction of Stem Cell Assay Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Assay Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Assay Market, By Deployment Model

5.1 Overview

6 Stem Cell Assay Market, By Solution

6.1 Overview

7 Stem Cell Assay Market, By Vertical

7.1 Overview

8 Stem Cell Assay Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Assay Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=ITN&utm_medium=003

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Assay Market Size, Stem Cell Assay Market Growth, Stem Cell Assay Market Forecast, Stem Cell Assay Market Analysis, Stem Cell Assay Market Trends, Stem Cell Assay Market

Read more from the original source:
Stem Cell Assay Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 - Instant Tech News

Read More...

Global Marine Selective Catalytic Reduction System Market Industry: A Latest Research Report to Share Market Insights and Dynamics – News Parents

February 17th, 2020 9:55 pm

The Marine Selective Catalytic Reduction System Market is prepared through a rigorous and unique format to offer a high-quality, accurate, and valuable insight to assist in making strategic business choices. The preparation of the report required our experts to contemplate on global, regional, segmental, and other market figures such as revenue, volume, CAGR, and market share to provide reports of highest quality.

Crucial dynamics related to the financial outlooks of leading players such as PANASIA, Hitachi Zosen, MAN Energy Solutions, Agriemach, Hug Engineering, DCL International, etc. their research and development statuses, and their expansion strategies for the coming years have been also listed in the Global Marine Selective Catalytic Reduction System Market report. In addition, sales volume, price, revenue, gross margin, historical growth and future perspectives have also been included in the report.

Have some queries? Get Free Sample PDF Copy of Latest Research on Marine Selective Catalytic Reduction System Market @ https://www.acquiremarketresearch.com/sample-request/305365/

The report also provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Marine Selective Catalytic Reduction System market are: PANASIA, Hitachi Zosen, MAN Energy Solutions, Agriemach, Hug Engineering, DCL International, Caterpillar, ECOUREA, ME Production, DEC Marine

Marine Selective Catalytic Reduction System Market Growth by Types: Small Marine Engines, Medium Marine Engines, Large Marine Engines

Marine Selective Catalytic Reduction System Market Extension by Applications: Commercial, Offshore, Recreational, Navy, Others

The Global version of this report with a geographical classification would cover regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/305365/

While segmentations have been provided to list down various facets of the Marine Selective Catalytic Reduction System market, analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. Summarization of various aspects consisted in the report have been listed.

Here are the important points covered in the report: 1.Complete assessment of opportunities and risk factors involved in the growth of Marine Selective Catalytic Reduction System Market. Additionally, major events and innovations in Marine Selective Catalytic Reduction System Market report.2.Technological advancements and changing trends striking Marine Selective Catalytic Reduction System Market.3.Get to know about the leading market players, both current and emerging in the Global Marine Selective Catalytic Reduction System.4.The report focuses on global major leading Marine Selective Catalytic Reduction System Market players providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information.

Have Any Query? Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/305365/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Marine Selective Catalytic Reduction System Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Read the original:
Global Marine Selective Catalytic Reduction System Market Industry: A Latest Research Report to Share Market Insights and Dynamics - News Parents

Read More...

Stem Cell Alopecia Treatment Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 – Instant Tech News

February 17th, 2020 9:55 pm

Stem Cell Alopecia Treatment Market Overview:

In the report, we thoroughly examine and analyze the Global market for Stem Cell Alopecia Treatment so that market participants can improve their business strategy and ensure long-term success. The reports authors used easy-to-understand language and complex statistical images, but provided detailed information and data on the global Stem Cell Alopecia Treatment market. This report provides players with useful information and suggests result-based ideas to give them a competitive advantage in the global Stem Cell Alopecia Treatment market. Show how other players compete in the global Stem Cell Alopecia Treatment market and explain the strategies you use to differentiate yourself from other participants.

The researchers provided quantitative and qualitative analyzes with evaluations of the absolute dollar opportunity in the report. The report also includes an analysis of Porters Five Forces and PESTLE for more detailed comparisons and other important studies. Each section of the report offers players something to improve their gross margins, sales and marketing strategies, and profit margins. As a tool for insightful market analysis, this report enables players to identify the changes they need to do business and improve their operations. You can also identify key electrical bags and compete with other players in the global Stem Cell Alopecia Treatment market.

Request a Report Brochure @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=ITN&utm_medium=001

Top 10 Companies in the Stem Cell Alopecia Treatment Market Research Report:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute

Stem Cell Alopecia Treatment Market Competition:

Each company evaluated in the report is examined for various factors such as the product and application portfolio, market share, growth potential, future plans and recent developments. Readers gain a comprehensive understanding and knowledge of the competitive environment. Most importantly, this report describes the strategies that key players in the global Stem Cell Alopecia Treatment market use to maintain their advantage. It shows how market competition will change in the coming years and how players are preparing to anticipate the competition.

Stem Cell Alopecia Treatment Market Segmentation:

The analysts who wrote the report ranked the global Stem Cell Alopecia Treatment market by product, application, and region. All sectors were examined in detail, focusing on CAGR, market size, growth potential, market share and other important factors. The segment studies included in the report will help players focus on the lucrative areas of the global Stem Cell Alopecia Treatment market. Regional analysis will help players strengthen their base in the major regional markets. This shows the opportunities for unexplored growth in local markets and how capital can be used in the forecast period.

Regions Covered by the global market for Smart Camera:

Middle East and Africa (GCC countries and Egypt)North America (USA, Mexico and Canada)South America (Brazil, etc.)Europe (Turkey, Germany, Russia, Great Britain, Italy, France etc.)Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=ITN&utm_medium=001

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=ITN&utm_medium=001

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

See original here:
Stem Cell Alopecia Treatment Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis and Forecast by 2026 - Instant Tech News

Read More...

Human Primary Cells Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 – News Parents

February 17th, 2020 9:55 pm

Human Primary Cells Market research report 2019 gives detailed information of major players like manufacturers, suppliers, distributors, traders, customers, investors and etc. Human Primary Cells market Report presents a professional and deep analysis on the present state of Human Primary Cells Market that Includes major types, major applications, Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export and etc. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.The growth trajectory of the Global Human Primary Cells Market over the assessment period is shaped by several prevalent and emerging regional and global trends, a granular assessment of which is offered in the report. The study on analyzing the global Human Primary Cells Market dynamics takes a critical look at the business regulatory framework, technological advances in associated industries, and the strategic avenues.

Get Exclusively Free Sample Of This Report in PDF @ https://www.upmarketresearch.com/home/requested_sample/96652

Prominent Manufacturers in Human Primary Cells Market includes LonzaThermo Fisher ScientificSigma-AldrichCell BiologicsPromoCell GmbHCurelineZen-BioSTEMCELL TechnologiesCell ApplicationsPelobiotechCreative BioarrayCharles River LaboratoriesAxol BioscienceReachBio Research Labs

Market Segment by Product Types Epithelial CellsFibroblastsHematopoieticLiver CellsMesenchymal Stem CellsMuscle CellsPericytes

Market Segment by Applications/End Users MedicalSantific ResearchOther

In order to identify growth opportunities in the market, the report has been segmented into regions that are growing faster than the overall market. These regions have been potholed against the areas that have been showing a slower growth rate than the market over the global. Each geographic segment of the Human Primary Cells market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

To Buy This Full or Customized Report, Please Visit https://www.upmarketresearch.com/buy/human-primary-cells-market-research-report-2019

Additionally, the complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. Factors in relation to products like the products prototype, manufacturing method, and R&D development stage are well-explained in the global Human Primary Cells market research report with point-to-point structure and with flowcharts. It offers a comparative study between conventional and emerging technologies and the importance of technical developments in this market. At last, the market landscape and its growth prospects over the coming years have been added in the research.

For Any Information About This Report, Visit https://www.upmarketresearch.com/home/enquiry_before_buying/96652

The Questions Answered by Human Primary Cells Market Report: What are the Key Manufacturers, raw material suppliers, equipment suppliers, end users, traders and distributors in Human Primary Cells Market? What are Growth factors influencing Human Primary Cells Market Growth? What are production processes, major issues, and solutions to mitigate the development risk? What is the Contribution from Regional Manufacturers? What are the Human Primary Cells Market opportunities and threats faced by the vendors in the global Human Primary Cells Industry? What are the Key Market segments, market potential, influential trends, and the challenges that the market is facing?And Many More

Ask For Discount On This Report At https://www.upmarketresearch.com/home/request_for_discount/96652

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

Go here to see the original:
Human Primary Cells Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 - News Parents

Read More...

Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? – Forbes

February 17th, 2020 9:53 pm

A hamburger made out of cell-based meat by Mosa Meat, one of many companies throughout the world ... [+] creating beef and other animal products without the animal.

Up until now, plant-based food companies like Beyond Meat, Impossible Foods, and Quorn have almost singlehandedly worked to lessen the impacts of industrial animal agriculture.

Supermarket shelves and fast food restaurants across the US are serving up vegan burgers and meatballs and plant-based chicken nuggets are showing consumers there is an alternative to relying on animal-based protein.

But a quiet revolution is also taking place in labs, where scientists are working to cultivate meat and seafood grown from cells, with the potential to reduce demand for industrial animal agriculture even further.

Heres how the process works: Stem cells are taken from the muscle of an animal, usually with a small biopsy under anesthesia, then theyre put with nutrients, salts, pH buffers, and growth factor and left to multiply. Finessing the technology and getting the cost to an affordable level is happening at a slower pace than the plant-based industry, but a number of start-ups are nevertheless aiming to get their products on the market soon.

Memphis Meats' pan-seared cell-based chicken with sugar snap peas.

Cell-based meat (also known as cultured, cultivated, slaughter-free, cell-cultured, and clean meat) could be a common sight in supermarkets across the west in the next three years, according to theInstitute of the Future in Palo Alto. California-based Memphis Meats made headlines for its world-first cell-based meatballs four years ago, and iscurrently building a pilot plantto produce its cultured beef, chicken, and duck on a bigger scale with plans to launch more plants around the world.

And it isnt the only cell-based meat start-up in the The Golden State. Theres the recently formed San Francisco-basedArtemys Foods, co-founded by biochemist Jess Krieger, who has spent the past six years working at Kent State University in Ohio growing cell-based meat in a lab, Berkeley-basedMission Barns, focusedon creating animal fat, which it has mixed with other ingredients to make duck sausages, and San Diego-based BlueNalu, a startup developing seafood from fish cells through a process called cellular aquaculture.

Close up of BlueNalu's whole-muscle, cell-based yellowtail, beer-battered and deep-fried for fish ... [+] tacos.

But innovation isnt limited to the US its happening across the world.The global cell-based meat market is predicted to be worth$15.5m by 2021 and $20m by 2027,according to analysis.One report estimates that35% of all meat will be cultured by 2040.

While estimates vary, one study found that cell-based beef is projected to use 95 per cent fewer global greenhouse gas emissions, 98 per cent less land use and up to half as much energy. It also significantly reduces the amount of antibiotics needed, which are widely used in agriculture and contribute hugely to worseningantibiotic resistance. And since the animal cells are extracted humanely and grown in a facility rather than within the animals themselves, cell-based meat has the potential to all but eliminate animal suffering.

The industry has made huge progress since the first cell-based hamburger was unveiled in 2013 in London byDutch stem cell researcher Mark Post, chief scientific officer atDutch companyMosa Meat.While this was a huge achievement, it also showed the world how far the industry had to go before commercially viable cell-based meat could be a reality. It cost $325,000 to make, and wasnt totally animal-free, as most of the burgers muscle strands were grown with fetal bovine serum, which comes from blood drawn from bovine fetuses.

In the intervening years, Mosa Meat has made several breakthroughs, and aims to bring the price down to a commercial price. It now doesnt require fetal bovine serum, and hasdeveloped a process thatallows industrial scale production.

Cell-based tartar (raw minced beef, commonly eaten in some of the Northern European countries), ... [+] created by Mosa Meat.

Also in the Netherlands, start-up Meatable has recently raised 9m to help reduce costs and scale-up production of its beef and pork. It aims to havean industry-scale plant by 2025,and will have a small-scale bioreactor the machine where cell-growth takes place - this year.Meatables cofounder Krijn de Nood hopes tounveil its first prototype this summer.

Elsewhere in Europe, the UKs Higher Steaks is growing stem cells for the production of mince for pork sausages. Instead of using fetal bovine serum,the company uses protocols exclusively licensed to itby its collaborators, the University of Minnesota, that allow it to reprogram stem cells into muscle and fat tissues.

Instead of adult stem cells, it uses induced pluripotent stem cells, which means they have an infinite supply as the cells proliferate infinitely. With adult stem cells, researchers have to go to the animal every time they need a new batch.

AndSpains Cubiq Foodsis producing cell-based fat, which is used to enhance the flavor of food and enrich it with essential fatty acids, such as omega-3.

But when it comes to cell-based meat, all eyes are on Israel, where a number of start-ups likeFuture Meat Technologies and SuperMeat are making huge progress. The countrys interest in cell-based meat has also been attributed to its thriving vegan culture.

Comparison of Future Meat Technologies' cell-based chicken (left) to of farm-raised chicken (right). ... [+]

Future Meat Technologies, founded in 2018, has shortened the manufacturing process to two weeks, with a patent-pending method they say allows for higher production yields of cell-based beef. The start-up's technologies enable producers, farmers and retailers to manufacture biomass and process it locally. The company hopes toget cost down to $10 per poundby 2022.

As for SuperMeat, it is developing cell-based meat from chicken cells (it claimed during its launch in 2016 that it wasthe first company to work on clean chicken productsfor mass production). One of Europe's largest poultry producers,PHW-Gruppe formed a partnershipwith SuperMeat in 2018. We believe 2020 will be the tipping point for the cultivated meat industry, once the proof of scale will be introduced to the world, says Shir Friedman, Co-Founder and Chief Communications Officer of the company. SuperMeat is excited to take a lead part in this historical event."

An illustration of SuperMeat's cell-based meat cultivators of the future.

Another Israeli start-up,Aleph Farms, created the worlds first cell-based steak at the end of 2018.It was co-founded only one year prior together with The Kitchen Hub from the Strauss Group, and with Professor Shulamit Levenberg of the Technion Institute of Technology. And in fall of 2019,Aleph Farmssuccessfully3D printedmeat on the International Space Station. Our experiment ofbioprintingmeat in space... consisted of printing a small-scale muscle tissue using 3D Bioprinting Solutions bioprinting technology, says Yoav Reisler, External Relations Manager for the company. The proof of concept sought to assess the potential of producing cultivated meat in a zero-gravity environment away from land and local water resources. Our approach for cultivating beef steaks is imperative to the experiment, as it relies on mirroring the natural process of tissue regeneration that happens in a cows body but under controlled and animal-free conditions. Our overarching goal is to produce meat products that have a significantly reduced ecological impact and this was a milestone in towards achieving that. Earlier this month, Aleph Farms announced plans to open an educational complex next to its production facility to provide the general public a more in-depth view of how cell-based meat is grown.

Thin-cut beef steaks cultivated by Aleph Farms.

Also in Israel,BioFood Systemsaims to produce beef products using bovine embryonic stem cells. It also hopes to scale up technology that it can license globally toenable meatmanufacturers to produce their own cell-based meat.

But other parts of the world arent far behind Israel, including Asia. Singaporean Shiok Meats is working on bringing cell-based based crustaceans (shrimp, crab and lobster) to market, and says its the first company of its kind in Singapore and South-East Asia. It hopes to have a commercially viable product in the next few years, and is currently researching and developing.

Shiok Meats cell-grown shrimp dumplings.

And in Japan, meat producer Toriyama and its export agent, Awano Food Group has partnered with JUST to grow, distribute and sell its cell-based wagyu beef worldwide.

JUST doesn't yet have images of its cell-based wagyu because its still in early stage R&D, but it ... [+] may one day look like this animal-based piece of Wagyu beef steak seen here.

In-between Asia and Europe, innovation is also happing in Turkey. Biftek is the first and still the only companydeveloping cultured meat in the country. It uses a plant-based formulation, made up of 44 proteins, in place of fetal bovine serum. Founder Can Akcali said in a recent interview that the media in Turkey is showing a growing interest in its work, and cell-based meat more widely.

Since the first cell-based unveiling of a cell-based burger in 2013, scientists have been flocking to labs in a race to iron out numerous teething problems and be the first to make a commercially viable cell-based meat product. Meanwhile, private investment into the industry has soared. Last year, twelve companiesraised $50 million in 14 deals double the amount of 2018. US-based Memphis Meats raised $22 million, Spain's Cubiq Foods raised $14 million and Mosa Meat drew in $9 million.

Memphis Meats now plans to build a pilot production facility,thanks to additional investments in January this yearfrom Cargill and Tyson Foods, as well as high-profile investors Bill Gates, Richard Branson, and Kimbal Musk.

Ido Savir, SuperMeats chief executive, said Mosa Meat introduced the concept of cell-based meat to the world, and that the main challenge start-ups are still facing is proof of scaling up production to a commercially viable size that's cost-efficient. Once these hurdles are overcome, it will be a much smoother process to get cell-based meat on shelves. At the moment, cell-based products are being prototyped in labs - but once scientists have finessed the process and the cost, theyre produced at scale and can grow in facilities like any other food.

Many cell-based start-ups expect to get their products to market in the next few years. Whether or not they are actually able to meet that projection is an open question. I worry most startups in the cultured meat space are overestimating their short-term timeline to get to market and underestimating their potential long-term impact on completely redesigning our food system from the cell-level up, says Max Elder, Research Director in the Food Futures Lab at Institute for the Future. Regardless of the timeline, one thing is clear: we desperately need to undo the damage industrialized animal agriculture is wreaking on our communities, animals, and the planet. While it may indeed be unwise to count our cultured chickens before they hatch, especially in light of the urgent challenges we are facing, we can no doubt expect more innovation in the coming years. Perhaps one day - even if not in the near future - all the meat on our plates will indeed be slaughter-free.

Visit link:
Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes

Read More...

The Benefits of Intermittent Fasting – The New York Times

February 17th, 2020 9:53 pm

Although there have been a number of recent studies assessing the effects of intermittent fasting on people, none are long term, and the vast majority of disease-related findings stem from research on laboratory animals. For example, in an animal model of stroke, those fed only intermittently suffered less brain damage because they were better able to resist the stress of oxygen and energy deprivation.

Other animal studies have shown a robust disease-modifying benefit of intermittent fasting on a wide range of chronic disorders, including obesity, diabetes, cardiovascular disease, cancers and neurodegenerative brain diseases, the researchers reported. Their review of both animal and human studies found improvements in a variety of health indicators and a slowing or reversing of aging and disease processes.

For example, human studies of intermittent fasting found that it improved such disease indicators as insulin resistance, blood fat abnormalities, high blood pressure and inflammation, even independently of weight loss. In patients with multiple sclerosis, intermittent fasting reduced symptoms in just two months, a research team in Baltimore reported in 2018.

If you think evolutionarily, Dr. Mattson said, predators in the wild fight for prey in the fasting state and are better at recovering from inevitable injuries. The human counterpart people who evolved in feast-or-famine environments would not have survived unless somehow protected by fasting.

Our human ancestors did not consume three regularly spaced large meals, plus snacks, every day, nor did they live a sedentary life, the researchers wrote. The studies they analyzed showed that most if not all organ systems respond to intermittent fasting in ways that enable the organism to tolerate or overcome the challenge and then return to normal.

Dr. Mattson explained that during a fast, the body produces few new proteins, prompting cells to take protein from nonessential sources, break them down and use the amino acids to make new proteins that are essential for survival. Then, after eating, a lot of new proteins are produced in the brain and elsewhere.

A reasonable question might be How safe is intermittent fasting? When fats are used for energy, they produce substances called ketone bodies that regulate the expression and activity of many proteins and molecules that are known to influence health and aging, the researchers reported. Ketosis, a build-up of acidic ketones in the blood, is a state that the Atkins diet, the ketogenic diet and other carbohydrate-restricted diets aim to achieve. Taken to extremes, however, ketosis can damage the liver, kidneys and brain and is especially dangerous to people with various chronic disorders like diabetes and heart disease.

Follow this link:
The Benefits of Intermittent Fasting - The New York Times

Read More...

Validea’s Top Five Healthcare Stocks Based On Motley Fool – 2/16/2020 – Nasdaq

February 17th, 2020 9:53 pm

The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

CORCEPT THERAPEUTICS INCORPORATED (CORT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CRISPR THERAPEUTICS AG (CRSP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Motley Fool has returned 625.78% vs. 240.03% for the S&P 500. For more details on this strategy, click here

About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More here:
Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/16/2020 - Nasdaq

Read More...

10 Best Clinics for Stem Cell Therapy in Costa Rica [2020 …

February 17th, 2020 9:51 pm

Stem Cell Therapy involves the use of stem cells to treat different diseases. These are non-differentiated cells of a multicellular organism. All the cells in the body are specialized for a specific function but they are the only cells without an assigned function. They can differentiate into any type of cell as and when required by the body and can proliferate rapidly to produce multiple copies of a specific type. Sources of stem cells are embryos and adult body tissues. In the adults, stem cells are present in bone marrow, brain, liver, skin, skeletal muscles, blood and blood vessels. While embryonic stem cells are derived from a blastocyst. Nowadays, Umbilical cord is being stored under suitable conditions to get stem cells from it if needed. This is useful as chances of transplant rejection are less because stem cells are derived from your own umbilical cord.

Bone Marrow Transplant is the most commonly used method to treat various types of cancers such as lymphoma, multiple myeloma, and leukemia, etc. through stem cells. It is also used to treat brain diseases, cardiovascular diseases and cell deficiencies such as diabetes mellitus. Recently, anti-aging stem cell treatments have gain fame. It is used to restore your youth and beauty.

The procedure of stem cell therapy starts with removing stem cells from your body or from the donors body. The cells are collected from different body parts depending upon the need. After collection, the cells are processed according to the purpose for which they are extracted. The processed stem cells are injected into the specific area of your body using ultrasound or X-ray guidance. Anesthetics are used and the procedure is done under sterile conditions. It is necessary to make sure that the cells are reaching the desired area so that the improvement is better and quicker. There are three types of stem cell transplant:

Each type of stem cell transplant involves different methods, procedures, and techniques with different side effects and risks. The one suitable for you depends upon your age, health, and physical conditions.

The length of stay in the hospital varies in accordance with the condition for which stem cell therapy is being done. It is usually a 3 to 4 hours procedure (in-patient) in which stem cells are introduced into the body using syringes or catheter. Different factors are considered to decide the length of your stay in the hospital. These factors are:

Your stay in the hospital is longer for an allogeneic transplant as compared to an autologous transplant and you're free to leave Costa Rica the very next day, although it's advised to stay at least a few days in case you have further questions for the medical staff. But of course, these can be asked over the phone/email or directed towards your local medical team back home.

Complete recovery time varies from 2 to 12 weeks when the patient begins to feel pain relief. However, you can return to your routine work a couple of days after going through the transplant. Recovery depends upon your physical condition before and after the transplant. Over a period of 6 to 12 months, further improvements are seen in the patients. During the process, antibiotics and other drugs are prescribed. These drugs prevent transplant rejection and graft-host diseases. Allogenic stem cell transplant takes longer to recover than an autologous transplant.

It is advised to keep in contact with your doctor and to visit him/her on a regular basis. Apart from this, the following points should be considered:

There is asignificant success rate seen in patients having gone through the transplant, however, it is not always successful due to various reasons, one being the transplant rejection. This is common in the allogeneic type of stem cell transplant.

Exosomes are being used as an alternative to stem cell therapy. They are lipid bilayer surrounded vesicles secreted by live cells. They contain mRNA, proteins, chaperons, and various signaling molecules. They work as a natural carrier system for the transport of these substances. They function as a messenger within the body carrying information from one cell to the other. Stem cell therapy can be enhanced using exosomes. They help the bodys natural healing ability to increase the pace of recovery. Sometimes, stem cell therapy and exosomes are given together for better results.

Stem cell therapy is mostly being used for the treatment of cancer patients. Before the therapy, cancer cells are present within the body. After going through the therapy, stem cells replace cancer cells with healthy cells. This treats cancer, giving the patient a healthy life.

Go here to see the original:
10 Best Clinics for Stem Cell Therapy in Costa Rica [2020 ...

Read More...

Page 677«..1020..676677678679..690700..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick